Chronic Prostatitis

1. My Clinical Experience with Chronic Prostatitis

Chronic prostatitis is one of the most misunderstood and poorly managed urological conditions. In my practice in Rhodes, I frequently see patients who have spent months or years with chronic pelvic pain, taking repeated courses of antibiotics — without an infection ever being documented.

My Approach

According to the AUA 2025 Guideline:

• Distinguishing CBP from CP/CPPS as the first step — correct classification determines whether antibiotics are needed at all.
• Phenotypic evaluation using UPOINT for every CP/CPPS patient — identifying the six domains contributing to the clinical picture.
• Multimodal, individualised treatment targeting the patient’s specific mechanisms.
• Multidisciplinary collaboration with a specialised pelvic floor physiotherapist, a psychologist, and — where indicated — a pain specialist.
• Rational antibiotic use (antimicrobial stewardship): antibiotics only when infection is documented — never as a “trial”.

2. NIH Classification: From CBP to CP/CPPS

The internationally accepted National Institutes of Health (NIH/NIDDK) classification divides prostatitis into four categories:

Why Correct Classification Matters So Much

The large majority (>90%) of men with chronic pelvic pain have CP/CPPS — not an infection. Empirical, repeated antibiotic use in these patients:

• Does not improve symptoms.
• Increases antimicrobial resistance at a population level.
• Delays real, effective treatment.
• Contributes to adverse effects (Clostridioides difficile, fluoroquinolone-related tendinopathy).

3. Epidemiology & Impact on Quality of Life

CP/CPPS affects 2–10% of adult men worldwide, accounting for around 8% of urology visits. The average age at diagnosis is 35–45 years, with a significant impact during the most productive years of life:

• Around 25% of patients report lost working hours.
• Around 50% reduce their social and recreational activity.
• Rates of depression and anxiety are 2–3 times higher than in the general population.
• Sexual dysfunction (erectile, ejaculatory) coexists in 40–60% of cases.

4. Pathophysiological Mechanisms

4.1 Chronic Bacterial Prostatitis (CBP)

CBP is characterised by pathogens trapped within the prostatic ducts, often as a biofilm that protects them from antibiotics and the immune response. Pathogens by frequency:

• Escherichia coli (75–80%)
• Klebsiella spp., Proteus spp., Enterobacter spp.
• Enterococcus faecalis
• In young, sexually active men: Chlamydia trachomatis, Mycoplasma genitalium, Ureaplasma urealyticum

Frequent recurrence with the same pathogen is the characteristic clinical feature.

4.2 CP/CPPS — A Multifactorial Syndrome

The cause of CP/CPPS is complex and multifactorial. The main mechanisms supported by current research:

5. Symptoms & Clinical Picture

The hallmark symptom is chronic pain or discomfort lasting ≥3 months (within the last 6 months). The location can vary significantly:

6. Diagnostic Algorithm (AUA 2025)

According to the AUA 2025 Guideline Part I, CP/CPPS is a diagnosis of exclusion. Other causes of chronic pelvic pain must be systematically ruled out.

6.1 Detailed History

• Pain characteristics: location, quality, duration, aggravating/relieving factors.
• Urinary, sexual, and bowel symptoms — actively asked about, as patients often hesitate to volunteer them.
• Psychosocial burden: anxiety, depression, sleep quality.
• Previous treatments — particularly antibiotic courses (if they did not work, repeating them is not warranted).
• Comorbidities: irritable bowel syndrome (IBS), fibromyalgia, metabolic syndrome.

6.2 Physical Examination

• Inspection and palpation of the abdomen, groin, and scrotum.
• Digital Rectal Examination (DRE): assessment of the prostate, but mainly of the pelvic floor muscles for trigger points and overactivity (strong AUA 2025 recommendation).
• External palpation of the perineum and ischiocavernosus muscles.

6.3 Laboratory Work-Up

• Urinalysis and urine culture (to rule out infection).
• PCR/NAAT for Chlamydia and gonorrhoea in young, sexually active men.
• PSA: on a case-by-case basis, guided by age and risk factors for prostate cancer. Note: PSA can be falsely elevated in the inflammatory subtype of CP/CPPS.

6.4 Specialised Tests for CBP

When Chronic Bacterial Prostatitis is suspected (recurrent UTIs):

• The Meares-Stamey 4-glass test or the simplified 2-glass test: comparing bacterial load in urine before and after prostatic massage — the reference method for localising the infection.
• Culture of Expressed Prostatic Secretions (EPS).
• Semen culture as an alternative.

6.5 Uroflowmetry & Post-Void Residual (PVR)

When significant LUTS coexist, the EAU recommends uroflowmetry and PVR measurement before any treatment decision.

6.6 Imaging

Not routine. Transrectal ultrasound (TRUS) or mpMRI is indicated when there is suspicion of prostate abscess, prostate stones, seminal vesicle pathology, or inconsistent PSA findings.

7. NIH-CPSI: The International Symptom Score

The NIH Chronic Prostatitis Symptom Index (NIH-CPSI) is the internationally recognised, validated questionnaire for objectively quantifying CP/CPPS symptoms. It consists of 9 questions across three domains:

Severity Categories

• 0–14: Mild symptoms
• 15–29: Moderate symptoms
• 30–43: Severe symptoms

The NIH-CPSI is used not only for initial assessment, but mainly for monitoring response to treatment. A reduction of ≥6 points is considered a clinically significant improvement.

8. UPOINT: The Phenotypic Classification System

The UPOINT phenotyping system is one of the most important developments in managing CP/CPPS over the past 15 years. It was developed by Shoskes & Nickel and forms the basis of modern phenotype-directed treatment.

UPOINT identifies six clinical domains, each of which may be positive or negative in a given patient:

Why UPOINT Works

Research has shown that when treatment is directed by UPOINT phenotype, around 84% of patients experience a clinically significant improvement (CPSI reduction ≥6 points) at 26 weeks. In comparison, a non-individualised approach has response rates of 30–40%.

9. Modern Treatment: A Phenotype-Directed Approach

9.1 Chronic Bacterial Prostatitis (CBP — NIH II)

CBP requires prolonged, targeted antibiotics guided by susceptibility testing, using agents with good prostatic penetration:

• Fluoroquinolones (ciprofloxacin, levofloxacin) — historically first-line, used with caution due to EMA/MHRA restrictions.
• Trimethoprim/sulfamethoxazole.
• Macrolides (azithromycin) or tetracyclines (doxycycline) — if intracellular pathogens are confirmed (Chlamydia, Mycoplasma).
• Fosfomycin for recurrent ESBL-producing strains (emerging evidence).

Treatment duration: 4–6 weeks, with a repeat urine culture after completion. In refractory cases, long-term, low-dose suppressive therapy may be considered.

9.2 CP/CPPS — Phenotype-Directed Multimodal Treatment

According to the AUA 2025 Guideline Part II:

9.3 Complementary Interventions

• Lifestyle changes: moderate aerobic exercise, reducing caffeine/alcohol/spicy food, avoiding prolonged sitting.
• Acupuncture: mentioned in EAU/AUA guidelines as a conditional recommendation in selected patients.
• Multidisciplinary approach in severe cases: urologist, pelvic floor physiotherapist, psychologist/psychiatrist, pain specialist.

9.4 What Is No Longer Recommended (AUA 2025)

10. Prognosis & Follow-Up

Prognosis

The course of CP/CPPS is fluctuating — with remissions and flares. With the correct phenotype-directed approach:

• 70–85% of patients experience a clinically significant improvement within 6 months.
• Complete cure is not always achievable — the goal is long-term management with a satisfactory quality of life.
• Patients with a shorter duration of symptoms (<1 year) and fewer positive UPOINT domains have a better prognosis.

Follow-Up Schedule

• Reassessment every 4–8 weeks during the initial treatment phase.
• NIH-CPSI at every visit for objective monitoring.
• UPOINT re-evaluation every 6 months — domains may change over time.
• Urine cultures only when CBP recurrence is suspected.

11. Differential Diagnosis: What Else Can Look Similar

Because CP/CPPS is a diagnosis of exclusion, other conditions that can cause similar symptoms must be systematically ruled out:

• Acute or recurrent bacterial prostatitis or Chronic Bacterial Prostatitis (CBP) — ruled out with cultures.
• Urethritis from sexually transmitted pathogens (Chlamydia, gonorrhoea) — ruled out with PCR/NAAT.
• Benign Prostatic Hyperplasia (BPH) with predominant urinary symptoms — distinguished with uroflowmetry and post-void residual.
• Bladder Pain Syndrome / Interstitial Cystitis — overlapping symptoms, particularly suprapubic pain with urgency.
• Prostate or bladder stones — ruled out with imaging when clinically suspected.
• Testicular/epididymal pathology (orchitis, epididymitis, scrotal ultrasound when there is local pain/swelling).
• Urethral stricture or other transurethral causes of chronic pain.
• Pudendal neuralgia — characteristically worse when sitting, better when standing.
• Musculoskeletal causes: sacroiliac joint dysfunction, abdominal wall/pelvic muscle groups.
• Colorectal/anal pathology: haemorrhoids, irritable bowel syndrome (IBS) — a common coexisting condition, not strictly a diagnosis of exclusion.
• Prostate cancer — does not typically cause pain at an early stage, but is checked when PSA is elevated or risk factors are present.

12. Ureaplasma & Mycoplasma: Detection Does Not Mean Causation

One of the most common points of confusion: many patients undergo PCR testing and receive a positive result for Ureaplasma urealyticum/parvum or Mycoplasma hominis. This does not automatically mean it is the cause of their symptoms.

• Ureaplasma spp. colonises the genitourinary tract of a significant proportion of sexually active adults without any symptoms — simple detection in an asymptomatic individual is not, on its own, an indication for treatment.
• Mycoplasma genitalium has a clearer pathogenic role in urethritis and is associated with increasing macrolide resistance — treatment, when clinically correlated, should be guided by susceptibility testing.
• International guidelines do not recommend a routine PCR “diagnostic hunt” for every possible microbe in patients with CP/CPPS without a clear clinical indication.
• Empirically giving macrolides/tetracyclines “just in case” for a positive finding unrelated to the symptom picture is not evidence-based and contributes to unnecessary antibiotic exposure.

13. Sexual Health & Fertility

Erectile Function

CP/CPPS is often associated with erectile dysfunction, mainly due to chronic pain, performance-related anxiety, and pelvic floor dysfunction — not because the prostate is being “destroyed”. Treating the underlying cause (pelvic floor physiotherapy, anxiety management) often improves erectile function as well.

Fertility

In couples having difficulty conceiving, chronic inflammation may in some cases affect semen parameters. A semen culture and semen analysis are recommended, with referral for andrological evaluation of infertility when there is a confirmed conception problem — not as a routine step for every asymptomatic couple.

14. The Patient Journey: From First Visit to Long-Term Management

1. 1

   Initial Assessment

   Detailed history, physical examination (including pelvic floor assessment), urinalysis/urine culture, NIH-CPSI.

2. 2

   Ruling Out Infection & Other Causes

   PCR/NAAT where indicated, PSA on a case-by-case basis, uroflowmetry/PVR if LUTS coexist.

3. 3

   Phenotypic Classification (UPOINT)

   Identifying the domains affecting the specific patient.

4. 4

   Individualised Treatment Plan

   A combination of targeted interventions per domain — not a “one drug for everyone” approach.

5. 5

   Follow-Up & Adjustment

   NIH-CPSI reassessment every 4–8 weeks, adjusting the plan based on response.

6. 6

   Long-Term Management

   The goal is stabilisation and improved quality of life, with realistic expectations for remissions/flares.

15. Frequently Asked Questions

Related Topics

References

1. Lai HH, Pontari MA, Argoff CE, et al. Male Chronic Pelvic Pain: AUA Guideline: Part I — Evaluation and Management Approach. J Urol 2025;214(2):116–126. doi:10.1097/JU.0000000000004564. PubMed
2. Lai HH, Pontari MA, Argoff CE, et al. Male Chronic Pelvic Pain: AUA Guideline: Part II — Treatment of CP/CPPS. J Urol 2025;214(2):127–137. doi:10.1097/JU.0000000000004565. PubMed
3. AUA Guideline on Male Chronic Pelvic Pain (2025). American Urological Association — auanet.org
4. EAU Guidelines on Chronic Pelvic Pain 2026. European Association of Urology — uroweb.org
5. EAU Guidelines on Urological Infections 2025 (Section on Bacterial Prostatitis) — uroweb.org
6. Shoskes DA, Nickel JC, et al. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology 2009;73:538–542.
7. Litwin MS, et al. The NIH Chronic Prostatitis Symptom Index (NIH-CPSI): development and validation. J Urol 1999;162:369–375. PubMed
8. Anderson RU, et al. Painful myofascial trigger points and pain sites in men with CP/CPPS. J Urol 2009;182:2753–2758.
9. Borgert B, Wallen E, Pham M. Prostatitis. JAMA 2025;334(11):1003. doi:10.1001/jama.2025.11499.